Direct answer: The most common clinical-trial recruitment challenges are an overestimated eligible population, burdensome study design, unclear participant information, slow follow-up, fragmented ownership, weak site capacity and poor visibility across the funnel. Address them by diagnosing each stage separately, involving sites and patients early, using approved and accessible communication, and keeping eligibility decisions with qualified study staff.
A diagnostic map for recruitment problems
| Observed problem | Possible constraint | First check |
|---|---|---|
| Few leads | Population estimate, channel reach or message | Reachable population by site and approved source |
| Many unreachable leads | Permission, data quality or delayed response | Source fields, consent basis and first-attempt process |
| Low pre-screen completion | Confusing, long or inaccessible interaction | Drop-off point and participant feedback |
| Queue before site review | Unowned handoff or insufficient qualified capacity | Age of records and named reviewer |
| High screen failure | Feasibility assumptions or criteria not testable early | Reasons confirmed at formal screening |
| Missed first visits | Logistics, burden or unclear expectations | Booking-to-attendance reasons |
This is a diagnostic tool, not a causal verdict. Validate hypotheses with sites and, where appropriate, patient or public contributors before changing approved recruitment processes.
Challenge 1: the reachable population is smaller than the spreadsheet
Incidence, prevalence or database counts do not equal reachable, eligible and willing participants. Competing studies, referral pathways, visit burden, language, transport and criteria that require unavailable evidence all reduce the practical pool.
Response: ask each site to show the path from its source population to the first protocol-critical filters. Separate “known in records”, “permitted to contact”, “likely to meet early criteria” and “able to attend”. Feed repeated barriers back to sponsor-level feasibility and study planning rather than asking sites to compensate with more outreach.
Challenge 2: the invitation creates uncertainty instead of understanding
A potential participant may not know why they were contacted, whether the study is care, what participation involves or who will see their information. More persuasive copy is not the remedy. Clear, approved and accessible information is.
Response: lead with why the person is being invited, what the next interaction is and that participation is voluntary. Provide a credible human contact. Test whether the material works for the intended population and formats, following the relevant ethics and regulatory process.
Challenge 3: every team performs a task, but nobody owns the journey
Campaign teams may optimise leads, vendors may report completed contacts and sites may focus on visits. A candidate can still wait between all three. Aggregate enrolment numbers reveal the problem too late.
Response: give each stage an owner, timestamp, allowed outcome and escalation. Review ageing queues by site. Add capacity before adding lead volume when the constraint is qualified review or appointment availability.
Challenge 4: automation hides uncertainty
Automation is useful when it reduces repetitive work and makes the handoff clearer. It becomes risky when a score appears more certain than the underlying answer, when exceptions disappear or when staff cannot reconstruct what was asked.
Response: preserve the approved question, the person’s response and any uncertainty. Make the human review visible. Nacar does not take the clinical eligibility decision; that remains with the study team.
Challenge 5: one process is copied across countries and sites
Language is only one layer of localisation. Referral structures, approvals, participant expectations, site staffing and public trial information differ across markets. In the EU, CTIS supports the trial lifecycle and makes defined trial information public; local implementation still matters.
Response: standardise the control points—approved content, permissions, auditability and clinical handoff—while allowing sites to document valid local routes. Never infer that a translated message is automatically approved or culturally usable.
What this means for sponsors, CROs and sites
Sponsors
Treat repeated recruitment friction as study-design and system evidence. Give teams a route to escalate constraints.
CROs
Compare sites by stage and context. Use monitoring to identify stuck handoffs, not to pressure unsafe shortcuts.
Sites
Report the constraint precisely: population, permission, contact, review, screening or visit capacity. Precision makes support actionable.
Frequently asked questions
Why do clinical trials struggle to recruit patients?
Often because feasibility assumptions, study burden, local pathways and operational capacity do not line up. Communication and lead generation matter, but they cannot repair every design or site-capacity constraint.
How can a team reduce screen failure?
Analyse confirmed failure reasons, improve feasibility assumptions and consider which protocol-critical facts can lawfully and reliably be checked earlier. Do not use pre-screening as a substitute for formal screening.
Can more advertising solve slow recruitment?
Only when reach is the true constraint. If leads are waiting for contact, qualified review or appointments, more advertising increases the queue rather than enrolment.
How should recruitment challenges be reported?
Use stage-level evidence: volume, timestamps, outcomes, reasons and site context. Separate observed facts from hypotheses and escalate recurring constraints to the team able to change them.
Primary sources
By
Pedro Torrecillas
Founder & CEO, Nacar.ai
Pedro has spent more than a decade building recruitment companies and products. At Nacar, he applies that operating experience to clinical-trial patient recruitment.
Published: · Updated:
